#NIPT Test Clinic UK

[conceptodiagnostics]

Are you confused about which non-invasive prenatal screening test (NIPT) is best? Then don't worry; this article will let you know.

[conceptoclinic-uk]

You Need to Know about The Hormonal Imbalance Test

There are certain problems related to hormonal imbalances in our body and it is very important to know about them by doing a test. Therefore, it is advised to get a hormonal imbalance test at a Health Care Solutions UK . Many people don’t know this and they face a lot of problems. So it’s better to get it tested beforehand. Additionally, both of these imbalances can result in signs including exhaustion, mood swings, digestive problems, and unexplained weight gain or loss. Because of this, it's crucial to preserve the balance of our endocrine system as a whole to keep it functioning properly. You need to avail yourself of the Harmony Prenatal Test UK from Concepto Diagnostics.

These are the main signs of hormonal imbalance suggested by the Diagnostic Clinic in the UK that you should watch out for.

Fatigue

Everybody gets tired occasionally. But with enough rest, water, and a balanced diet, you should be able to recover. Consider getting a thorough assessment of your hormone levels if you feel like you are taking care of yourself but are still worn out or just can't seem to bounce back.

Anxiety

It's not all in your brain, not at all. Each year, over 18% of Americans experience an anxiety-related disorder, and 7% experience a serious depressive illness. Because fluctuations in estrogen during menstrual cycles, pregnancy, or menopause are linked to increased depression, women may be at a higher risk.

Putting on weight or struggling to shed it

Usually, it's a result of their nutrient-poor diet and excessive exertion. The body interprets this effort as stress, and when the body is under stress, it enters "fight-or-flight" or survival mode and releases cortisol.

Skin and hair modifications

One quick indicator of a suspected hormonal imbalance is a rapid increase in acne. Androgens are one of the few hormones in play. Sebum can accumulate in your pores and lead to a breakout if your body generates too many androgens.

 Hormones are sophisticated, potent substances. Several symptoms might make you feel as though you don't have control over your body if one or more of them are out of balance. It's crucial to discuss your symptoms with the Nutrition consultant in the UK if they are new and persistent. You'll be able to feel like yourself again as soon as you seek out assistance and therapy.

 Also Read: 5 important concerns about the quality and safety of multivitamins

[blueorpinkuk]

Gender Blood Test Home Kit: Know Its Procedure!

The mid-pregnancy ultrasound might occasionally appear too far away at 20 weeks. Therefore, you could be persuaded to do a gender test at home.

Although it causes no damage, accuracy is a contested subject. Although it must be emphasized that there doesn't seem to be any independent research done to corroborate this, some kits assert a high degree of accuracy as early as six weeks, just like the 6-week Gender Blood Test in the UK.

Are gender blood test kits challenging to use?

Since they are not performed under the same sterile circumstances as when a phlebotomist (a blood draw technician) collects them in a clinical environment, at-home blood tests might be difficult. 

For instance, if your spouse touches the test, it might get contaminated, and the results could be incorrect.

Consider the following items, among others:

Possibility of contamination: The blood sample you submitted could already be tainted before it reaches your home.

Unknown lab settings: It's possible that the labs that handle gender DNA test kits don't have the same qualifications as those that do in-depth NIPT.

Early-gender DNA test kit providers may provide refunds for incorrect findings. Therefore, I would suggest taking the BlueorPink Gender Blood Test Home Kit.

How do I use it?

The early gender detection test in the UK is conducted on blood and often functions as follows:

You get a package with instructions, tools for taking blood samples, and envelopes for mailing the samples to labs.

You must pierce your finger with a lancet (or a snap device) and collect the blood in a tube to administer the test.

You submit the blood tube to a lab for examination.

The lab emails you the test results in a week (or sooner with expedited service), telling you whether the baby is a boy or a girl.

There are also tests based on urine; however, urine contains very little DNA, and these tests make no claims of accuracy. Therefore, you should consider getting an early gender blood test in the UK at the BlueorPink Clinic.

Final Thoughts 

At our BlueorPink Clinic, you may have a blood test to determine your gender as early as 9 weeks. Tests are available in our clinic starting at 10 weeks. Patients can attempt very accurate at-home DNA test kits or may also get our Early Gender DNA Test in the UK. 

If you want to learn more about gender prediction testing, keep reading our earlier posts.

Also Read: What is the importance of gut health in fertility and reproductive outcomes?

[imaginatal-blog]

[thepregnancyclinic]

The ethos of our clinic is to ensure that women receive accurate, evidence-based information and advice, so that they can confidently enjoy their pregnancy journey without any unnecessary anxiety.

[esglatestmarketnews]

Next Generation Sequencing (NGS) Market Overview, Trends, Competitive Landscape, Growth Outlook And Forecast till 2025

September 22, 2021: The global next generation sequencing market is anticipated to reach USD 21.4 billion by 2025. NGS market is expected to show a tremendous growth on account of its wide applications in the treatment of cancer. NGS is the process of identifying accurate order of nucleotides within a RNA or a DNA molecule. Advancement of NGS has helped biological and medical discovery and research. It has helped in various applied fields which includes biotechnology, forensic research, virology and medical diagnosis. NGS has made possible sequencing of DNA of various species including the human genome.

Introduction of advanced genetic sequencing and development of advance techniques for whole genomes are the major drivers contributing to the overall market growth. Increasing incidences of cancer and infectious diseases coupled with aging population is expected to fuel the demand for these technologies. Further, the overall cost of genome sequencing is expected to reduce drastically on account of rapid development through research and innovation. High capacity genome sequencing has been contributing significantly towards the market growth.

NGS has wide applications in the field of exome and genome sequencing. They are widely used in the treatment of infectious disease and cancer. NGS has shown a key presence in pathogen analysis which has been helpful in the treatment of infectious diseases. The need for effective diagnosis for cancer and high growing usage of combinational biomarkers are other factors contributing to the growth of the market in recent years.

Request a Free Sample Copy of this Report @ https://www.millioninsights.com/industry-reports/next-generation-sequencing-ngs-market/request-sample

NGS has been mostly a topic of research and development in the previous decade. At present they find applications in the field of oncology, prenatal testing, HLA testing, idiopathic diseases, and medical research. Research and development in the field of HLA and prenatal testing have provided new avenues to doctors in gaining insights during organ matching and organ rejection.

The development in the treatment of genetic anomalies and diseases with the help of prenatal genome sequencing has been driving the NGS market. This technology has also helped the pharmaceutical companies in developing essential drugs for the treatment of cancer and infectious diseases. Growing concerns and increasing incidences of cancer is expected to be the major driving factor for the development of NGS.

NGS in the field of organ transplant provides great opportunities over the forecast period. It is important that the characteristics of both the donors and the acceptors match for a successful transplant. NGS helps in studying the immune response to the transplanted organ. Medical tourism development in countries including the U.S, Israel, Singapore and Australia provide bright prospects for overall growth of the market.

Next generation sequencing market is segmented as target, genome, exon and resequencing. The largest share is held by target sequencing followed by genome sequencing. Development of whole genome sequencing capabilities is expected to show a significant growth over the forecast period. Whole genome technology is relatively new and is gaining popularity with the development of high throughput. This high throughput has helped in reducing complications associated with whole genome sequencing.

NGS includes sample enrichment, DNA tagging, library preparation, sample quality assurance, DNA quantification, data storage, genetic data assembly, analysis and interpretation. With the increase in volume of whole genome sequencing, next generation data analysis is expected to observe a significant growth over the forecast period.

Government regulatory bodies play a vital role in overall development and usage of these technologies. Medical device manufacturers in the U.S. are under the strict vigilance of Food and Drug Administration (FDA). In 2013, FDA approved four next generation gene sequencing devices which is expected to help physicians in taking a broader look at the patient’s genetic makeup. Two of the approved devices is expected to help in detecting DNA changes in the treatment of cystic fibrosis.

North America is expected to observe highest demand in the global industry on account of the well-developed healthcare sector and implementation of advanced research infrastructure. Similarly, Western Europe is expected to show a substantial demand over the forecast period on account of increasing emphasis by the regional government on healthcare facilities coupled with the stringent regulatory framework. Asia Pacific and the Middle East are expected to observe significant growth on account of the increasing government initiatives to establish proper healthcare infrastructure in developing economies including China, India, Japan and UAE.

Browse Full Research Report @ https://www.millioninsights.com/industry-reports/next-generation-sequencing-ngs-market

The NGS market is dominated by few players with the help of proprietary platforms. The key industry players include Life Sciences (Roche), Thermo Fischer Scientific, Illumina and Pacific Biosciences. Other major players operating in the market include Partek Inc., Genomatix Software GmbH, Macrogen Inc., Life Technologies Corp, Perkin Elmer inc., Oxford Nanopore Technologies Ltd., Knome Inc, Agilent Technologies Inc., Biomatters Ltd., CLC Bio (Qiagen), Pacific Biosciences, BGI (Beijing Genomics Institute), DNASTAR Inc, GATC Biotech and Qiagen N.V.

Market Segmentation

NGS Outlook, by Application (Revenue, USD Million; 2014 - 2025)

• Reproductive Health

• NIPT

• PGT

• Newborn/Genetic Screening

• Oncology

• HLA Typing/Immune System Monitoring

• Metagenomics, Epidemiology & Drug Development

• Agrigenomics & Forensics

• Consumer Genomics

• Clinical Investigation

• Idiopathic Diseases

• Inherited Diseases

• Infectious Diseases

• Non-Communicable / Other Diseases

NGS Outlook, by Technology (Revenue, USD Million; 2014 - 2025)

• Targeted Sequencing Analysis

• DNA Based Targeted Sequencing Analysis

• RNA Based Targeted Sequencing Analysis

• Whole Genome Sequencing

• Whole Exome Sequencing

NGS Outlook, by Workflow (Revenue, USD Million; 2014 - 2025)

• Pre-sequencing

• NGS Library Preparation Kits

• NGS Semi-automated Library Preparation

• NGS Automated Library Preparation

• Clonal Amplification

• Sequencing

• Data Analysis

• Primary Data Analysis

• Secondary Data Analysis

• Tertiary Data Analysis

NGS Outlook, by End-use (Revenue, USD Million; 2014 - 2025)

• Academic Research

• Clinical Research

• Hospitals & Clinics

• Pharma & Biotech Entities

• Other Users

NGS Outlook, by Region (Revenue, USD Million; 2014 - 2025)

• North America

• U.S.

• Canada

• Europe

• Germany

• UK

• Asia Pacific

• China

• Japan

• Latin America

• Brazil

• Middle East & Africa

• South Africa

Get in touch

At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

Contact Person:

Ryan Manuel

Research Support Specialist, USA

Email: ryan@millioninsights.com

[jesse-pinkman123]

Genomics Market Size, Share, Outlook, and Opportunity Analysis, 2019– 2027

Genomics Market by Product Type (Consumables, Software, and Others), by Technology (PCR, Microarray, Next Gene Sequencing, Nucleic Acid Extraction and Purification, and Others), by Application (Diagnostics, Drug Discovery and Development, Precision Medicine, Agriculture & Animal Research, and Others), by End Users (Academic and Research Institute, Pharmaceutical & Biotechnology Companies, Hospital and Clinics, and Others), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2019 – 2026

Genomics is the study of human genes and chromosomes. It focuses on structure, function, evolution, mapping, and editing of genomes. Genome is the genetic material of organism, which includes the Deoxyribonucleic acid (DNA). DNA consists the information needed to build the whole human body. Human genome consists of 23 pairs of chromosomes and 24000 genes. This study is divided into various types such as structural genomics, functional genomics, and comparative genomics.

Global Genomics Market Drivers

Increasing new product launches is expected to drive the global genomics market growth. For instance, in January 2019, Contextual Genomics launched two molecular hotspot assays (Liquid Biopsy Test and updated Solid Tumor Panel) for the detection of genomic mutations in blood and solid tumors.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2660

Furthermore, in May 2015, Rosetta Genomics Ltd. launched OncoGxOne. It is Next Generation Sequencing (NGS) test that profiles tumors for targeted therapy selection and chemotherapeutic tolerance.

Moreover, in September 2018, Zenome launched the first decentralized genomic internet software, which is expected to increase possibilities of safe storage of large amount of genetic data. The main advantage of decentralized genomic internet software is that the degree of security is much higher.

Global Genomics Market Restraints

Lack of qualified and trained professionals in genomics study is a major challenge for the global genomics market growth. For instance, in January 2019, according to express healthcare report, genomics study needs highly qualified and trained professionals to optimize lab workflows and run it efficiently.

Global Genomics Market Regional Analysis

Europe is expected to gain significant share in the global genomics market over the forecast period, owing to increasing launches of new products by key players. For instance, in April 2017, Illumina, Inc. announced launch of its new product VeriSeq NIPT Solution, it is a CE-IVD marked next-generation sequencing (NGS)-based approach to non-invasive prenatal testing (NIPT).

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/genomics-market-2660

This approach includes the CE-IVD marked library preparation and analysis software. This software enables fast, highly accurate, cost-effective, and non-invasive parenteral testing (NIPT).

Furthermore, Asia Pacific is also projected to witness significant growth in the global genomics market during the forecast period, owing to increasing collaboration activities by key players. For instance, in January 2018, 10X Genomics, Inc. collaborated with the Berry Genomics Co. Ltd. Under this collaboration, 10x Genomics, Inc. focuses on development of approaches for next generation non-invasive prenatal testing (NIPT) and developing and offering new services for Berry Genomics Co. Ltd.

Key players operating in the global genomics market include Thermo Fisher Scientific, Inc., Agilent Technologies, Bio-Rad Laboratories, Inc., Illumina, Inc., Pacific Biosciences, Oxford Nanopore Technologies., 23andMe, Inc., Foundation Medicine, Inc. Hoffmann-La Roche Ltd., and Myriad Genetics, Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2660

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737

[freefestwinner]

Global Newborn and Prenatal Genetic Testing Market Insights, Overview, Analysis and Forecast 2020

Summary - A new market study, titled Global Newborn and Prenatal Genetic Testing Market Report 2020" has been featured on WiseGuyReports.

At the beginning of 2020, COVID-19 disease began to spread around the world, millions of people worldwide were infected with COVID-19 disease, and major countries around the world have implemented foot prohibitions and work stoppage orders. Except for the medical supplies and life support products industries, most industries have been greatly impacted, and Newborn and Prenatal Genetic Testing industries have also been greatly affected.

ALSO READ: https://www.marketwatch.com/press-release/newborn-and-prenatal-genetic-testing-2020-global-market-outlookresearchtrends-and-forecast-to-2025-2020-10-07

In the past few years, the Newborn and Prenatal Genetic Testing market experienced a growth of xx, the global market size of Newborn and Prenatal Genetic Testing reached xx million $ in 2020, of what is about xx million $ in 2015.

 From 2015 to 2019, the growth rate of global Newborn and Prenatal Genetic Testing market size was in the range of xxx%. At the end of 2019, COVID-19 began to erupt in China, Due to the huge decrease of global economy; we forecast the growth rate of global economy will show a decrease of about 4%, due to this reason, Newborn and Prenatal Genetic Testing market size in 2020 will be xx with a growth rate of xxx%. This is xxx percentage points lower than in previous years.

 As of the date of the report, there have been more than 20 million confirmed cases of CVOID-19 worldwide, and the epidemic has not been effectively controlled. Therefore, we predict that the global epidemic will be basically controlled by the end of 2020 and the global Newborn and Prenatal Genetic Testing market size will reach xx million $ in 2025, with a CAGR of xxx% between 2020-2025.

 This Report covers the manufacturers’ data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.

Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers. If you need more information, please contact BisReport

 Section 1: Free——Definition

 Section (2 3): 1200 USD——Manufacturer Detail

Perkin Elmer

Verinata Health

Sequenom, Inc.

Agilent Technologies, Inc.

Bio-Rad Laboratories, Inc.

Natera, Inc.

Illumina, Inc.

Ariosa Diagnostics

BGI

CapitalBio MedLab

 Section 4: 900 USD——Region Segmentation

North America Country (United States, Canada)

South America

Asia Country (China, Japan, India, Korea)

Europe Country (Germany, UK, France, Italy)

Other Country (Middle East, Africa, GCC)

 Section (5 6 7): 500 USD——

Product Type Segmentation

PCR

FISH

aCGH

NIPT

MSS

 Industry Segmentation

Hospital

Clinic

 Channel (Direct Sales, Distributor) Segmentation

 Section 8: 400 USD——Trend (2020-2025)

 Section 9: 300 USD——Product Type Detail

 Section 10: 700 USD——Downstream Consumer

 Section 11: 200 USD——Cost Structure

 Section 12: 500 USD——Conclusion

FOR MORE DETAILS: https://www.wiseguyreports.com/reports/5879718-global-newborn-and-prenatal-genetic-testing-market-report-2020

About Us: Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.  

 Contact Us:

NORAH TRENT                                                    

sales@wiseguyreports.com      

Ph: +162-826-80070 (US)                          

Ph: +44 203 600 2763 (UK)      

[marketreasearch]

Global Hereditary Testing Market to Witness a Pronounce Growth During 2027

Hereditary testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to hereditary testing market.

Market Analysis and Insights: Global Hereditary Testing Market

Hereditary testing market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account toUSD 9.31 billion by 2027 growing at a CAGR of 6.10% in the above-mentioned forecast period. The accelerating generative hereditary health scope is one of the key market drivers.

The major players covered in the hereditary testing marketreport are F. Hoffmann-La Roche Ltd, Abbott, Amgen Inc., ELITechGroup, GW Pharmaceuticals plc, Thermo Fisher Scientific Inc., Pfizer Inc., PerkinElmer Inc., AutoGenomics, Bio-Rad Laboratories, Inc., BioMarin, Sarepta Therapeutics,Amicus Therapeutics, Inc., Alexion Pharmaceuticals, Inc., Sanofi, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated,among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa(MEA) and South America separately. DBMR analystsunderstand competitive strengths and provide competitive analysis for each competitor separately.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hereditary-testing-market

The harmonious upsurge in trade for new-born screening has pointed to an improvement in the commerce of DNA experiment equipment. Progressing keen-sightedness of new-born screening crosswise the earth is moreover supporting in earnings growth. Reformations in genetic experimentation guidelines beget headed to the formation of a multigene board trial for genetic melanoma into clinical application. Continuous advancements in the distribution model are expected to profit the genetic examination business. Technological amendments are performing a significant function in the market growth by enhancing their delivery assistance and progressing the effectiveness of the technology implied. Organizations are adopting a cloud-based administration design to compose bioinformatics technology accessible for employment by other labs. Expense and preservation solicitudes encountered by users of the analysis and the dearth of adequate supervision of the experiments can act as a restraint for the market.

This hereditary testing market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Data Bridge Market Research hereditary testing market contact us for an Analyst Brief,our team will help you take an informed market decision to achieve market growth.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-hereditary-testing-market

Global Hereditary Testing Market Scope and Market Size

Hereditary testing marketis segmented onthe basis of hereditary cancer testing and hereditary non-cancer testing. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based onhereditary cancer testing, the hereditary testing marketis segmented into lung cancer, breast cancer, colorectal cancer, cervical cancer, ovarian cancer, prostate cancer, stomach/gastric cancer, melanoma, sarcoma, uterine cancer, pancreatic cancer, and others.

Based on hereditary non-cancer testing, the hereditary testing market is segmented intogenetic tests, newborn genetic screening, preimplantation genetic diagnosis & screening, non-invasive prenatal testing (NIPT) & carrier screening tests. Genetic tests are further sub-segmented into cardiac diseases, rare diseases, and other diseases.

Hereditary Testing Market Country Level Analysis

Hereditary testing marketis analysed and market size insights and trends are provided by country,hereditary cancer testing and hereditary non-cancer testing as referenced above.

The countries covered in the hereditary testing marketreport are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa(MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the hereditary testing market due to the high prevalence of breast cancer patients, and entrance of the key market players and strong healthcare foundation.

The country section of the hereditary testing marketreport also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

For More Insights Get Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-hereditary-testing-market

Healthcare Infrastructure growth Installed base and New Technology Penetration

Hereditary testing marketalso provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for hereditary testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the hereditary testing market. The data is available for historic period 2010 to 2018.

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @ Corporatesales@databridgemarketresearch.com

[kisan512posts]

Prenatal and New-born Genetic Testing -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2025

Prenatal and New-born Genetic Testing Industry

Description

Wiseguyreports.Com Adds “Prenatal and New-born Genetic Testing -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023” To Its Research Database

This report studies the global Prenatal and New-born Genetic Testing market, analyzes and researches the Prenatal and New-born Genetic Testing development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like

Agilent Technologies, Inc. Bio-Rad Laboratories, Inc. Natera, Inc. Illumina, Inc. Ariosa Diagnostics Perkin Elmer Verinata Health Sequenom, Inc.

Market segment by Regions/Countries, this report covers United States EU Japan China India Southeast Asia

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/3005247-global-prenatal-and-new-born-genetic-testing-market-size-status-and-forecast-2025

Market segment by Type, the product can be split into PCR FISH aCGH NIPT MSS

Market segment by Application, Prenatal and New-born Genetic Testing can be split into Hospital Clinic Others

Table of Contents

Global Prenatal and New-born Genetic Testing Market Size, Status and Forecast 2025 1 Industry Overview of Prenatal and New-born Genetic Testing 1.1 Prenatal and New-born Genetic Testing Market Overview 1.1.1 Prenatal and New-born Genetic Testing Product Scope 1.1.2 Market Status and Outlook 1.2 Global Prenatal and New-born Genetic Testing Market Size and Analysis by Regions (2013-2018) 1.2.1 United States 1.2.2 EU 1.2.3 Japan 1.2.4 China 1.2.5 India 1.2.6 Southeast Asia 1.3 Prenatal and New-born Genetic Testing Market by Type 1.3.1 PCR 1.3.2 FISH 1.3.3 aCGH 1.3.4 NIPT 1.3.5 MSS 1.4 Prenatal and New-born Genetic Testing Market by End Users/Application 1.4.1 Hospital 1.4.2 Clinic 1.4.3 Others

...

3 Company (Top Players) Profiles 3.1 Agilent Technologies, Inc. 3.1.1 Company Profile 3.1.2 Main Business/Business Overview 3.1.3 Products, Services and Solutions 3.1.4 Prenatal and New-born Genetic Testing Revenue (Million USD) (2013-2018) 3.1.5 Recent Developments 3.2 Bio-Rad Laboratories, Inc. 3.2.1 Company Profile 3.2.2 Main Business/Business Overview 3.2.3 Products, Services and Solutions 3.2.4 Prenatal and New-born Genetic Testing Revenue (Million USD) (2013-2018) 3.2.5 Recent Developments 3.3 Natera, Inc. 3.3.1 Company Profile 3.3.2 Main Business/Business Overview 3.3.3 Products, Services and Solutions 3.3.4 Prenatal and New-born Genetic Testing Revenue (Million USD) (2013-2018) 3.3.5 Recent Developments 3.4 Illumina, Inc. 3.4.1 Company Profile 3.4.2 Main Business/Business Overview 3.4.3 Products, Services and Solutions 3.4.4 Prenatal and New-born Genetic Testing Revenue (Million USD) (2013-2018) 3.4.5 Recent Developments 3.5 Ariosa Diagnostics 3.5.1 Company Profile 3.5.2 Main Business/Business Overview 3.5.3 Products, Services and Solutions 3.5.4 Prenatal and New-born Genetic Testing Revenue (Million USD) (2013-2018) 3.5.5 Recent Developments 3.6 Perkin Elmer 3.6.1 Company Profile 3.6.2 Main Business/Business Overview 3.6.3 Products, Services and Solutions 3.6.4 Prenatal and New-born Genetic Testing Revenue (Million USD) (2013-2018) 3.6.5 Recent Developments 3.7 Verinata Health 3.7.1 Company Profile 3.7.2 Main Business/Business Overview 3.7.3 Products, Services and Solutions 3.7.4 Prenatal and New-born Genetic Testing Revenue (Million USD) (2013-2018) 3.7.5 Recent Developments 3.8 Sequenom, Inc. 3.8.1 Company Profile 3.8.2 Main Business/Business Overview 3.8.3 Products, Services and Solutions 3.8.4 Prenatal and New-born Genetic Testing Revenue (Million USD) (2013-2018) 3.8.5 Recent Developments

Report Detail’s @ https://www.wiseguyreports.com/reports/3005247-global-prenatal-and-new-born-genetic-testing-market-size-status-and-forecast-2025

Continued...                      

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us)  Ph: +44 208 133 9349 (Uk)

[thomasslobo-blog]

Global Preimplantation Genetic Testing Market 2019 | Manufacturers In-Depth Analysis Report to 2024

The latest trending report Global Preimplantation Genetic Testing Market 2019-2024 added by DecisionDatabases.com

Preimplantation genetic testing is a technique used to identify genetic defects in embryos created through in vitro fertilization (IVF) before pregnancy. Preimplantation genetic diagnosis (PGD) refers specifically to when one or both genetic parents has a known genetic abnormality and testing is performed on an embryo to determine if it also carries a genetic abnormality. In contrast, preimplantation genetic screening (PGS) refers to techniques where embryos from presumed chromosomally normal genetic parents are screened for aneuploidy.

The global Preimplantation Genetic Testing market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.

This report studies the Preimplantation Genetic Testing market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Preimplantation Genetic Testing market by product type and applications/end industries.

Browse the complete report and table of contents @ https://www.decisiondatabases.com/ip/37556-preimplantation-genetic-testing-market-analysis-report

Market Segment by Companies, this report covers

    Illumina

    Thermo Fisher

    Agilent Technologies

    Perkinelmer

    Coopersurgical

    Abbott Laboratories

    Natera

    Rubicon Genomics

    Oxford Gene Technology

    Yikon Genomics

    Scigene

    Beijing Genomics Institute

    Good Start Genetics

    Invicta Genetics

    Combimatrix

    Genea Limited

    Progenesis

Market Segment by Regions, regional analysis covers 

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

    Preimplantation Genetic Screening

    Preimplantation Genetic Diagnosis

Market Segment by Applications, can be divided into

    Maternity Centers & Fertility Clinics

    Hospitals, Diagnostic Labs, and Service Providers

    Research Laboratories & Academic Institutes

Download Free Sample Report of Global Preimplantation Genetic Testing Market @ https://www.decisiondatabases.com/contact/download-sample-37556

The content of the study subjects, includes a total of 15 chapters:

1 Preimplantation Genetic Testing Market Overview

2 Manufacturers Profiles

3 Global Preimplantation Genetic Testing Market Competition, by Players

4 Global Preimplantation Genetic Testing Market Size by Regions

5 North America Preimplantation Genetic Testing Revenue by Countries

6 Europe Preimplantation Genetic Testing Revenue by Countries

7 Asia-Pacific Preimplantation Genetic Testing Revenue by Countries

8 South America Preimplantation Genetic Testing Revenue by Countries

9 Middle East and Africa Revenue Preimplantation Genetic Testing by Countries

10 Global Preimplantation Genetic Testing Market Segment by Type

11 Global Preimplantation Genetic Testing Market Segment by Application

12 Global Preimplantation Genetic Testing Market Size Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

Purchase the complete Global Preimplantation Genetic Testing Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-37556

Other Reports by DecisionDatabases.com:

Global Non-Invasive Prenatal Testing (NIPT) Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

Global Infectious Disease Testing Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

Global Food Contaminant Testing Market 2019 by Company, Regions, Type and Application, Forecast to 2024

About-Us:

DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics. DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains.

Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors. We provide intellectual, precise and meaningful data at a lightning speed.

For more details: DecisionDatabases.com E-Mail: sales@decisiondatabases.com Phone: +91 9028057900 Web: https://www.decisiondatabases.com/

[growthscan]

Having a rainbow baby

A rainbow baby is the name for babies born after parents have experienced the loss of another child whether due to a miscarriage, or stillbirth or in the first month after birth.

The name stems from the fact that beautiful rainbows often follow a storm and can be a symbol of hope and comfort, after a dark time.

Losing a baby is devastating, and an emotionally-draining experience, as it goes against all your expectations and you are denied the happy ending that is the norm. Often it happens before you’ve told anyone you are pregnant, so others don’t understand why you’re upset or you make a choice to keep your grief hidden.

If you have conceived your rainbow baby after such a loss, you will understandably be more anxious and worried, particularly during the first trimester when miscarriage is more common, but perhaps then all through your pregnancy.

How scans may help your anxiety

Ultrasound scans give you images of your baby made up from sound waves with no known side effects. Scans can give you a detailed snapshot of your baby’s health and be a source of reassurance and detailed information throughout your pregnancy.

Ultrasound Direct have run a network of private clinics at 80+ locations offering private baby scans near you in the UK for 20 years. The company offers 14 different types of antenatal scan that can provide the extra scans you may want to think about for your rainbow baby. The clinics are run by expert obstetric sonographers, so you are in safe hands and appointments can be arranged to suit you, at a location near you.

Reassurance in the early days

The first 12 weeks of pregnancy can be worrying, as this is when miscarriage rates are highest. One in four pregnancies end in miscarriage and 85 per cent of these occur in the first trimester, [i]but a baby scan at a key point can be immensely reassuring. Even if the news isn’t good, just knowing what is happening so that you can deal with it, is often preferable to being left to fret and worry.

The NHS offers routine booking scans (sometimes called a dating scan) at between 8 and 14 weeks of your pregnancy and earlier if you experience spotting, bleeding, or cramping.

Ultrasound Direct offers early scans to provide you with the information and - in most cases - reassurance you need. These include:

·         Early scan: A 30-minute scan is offered at 6 to 11 weeks to find out if your pregnancy is viable and measuring correctly for your dates. It can also detect an ectopic pregnancy, where the baby is developing in a fallopian tube instead of the uterus.

·         Dating Scan: Performed at between 12 and 16 weeks, this 20-minute scan is also referred to as a 12-week scan or booking scan. The main purpose is to date your pregnancy by measuring your baby's size and confirm how many babies you're expecting. From 12 weeks, 4DFREEVIEW™ technology is available to give you a 3D moving picture of your baby, including their heart.

·         Babybond Nuchal Translucency (NT) Scan: Ultrasound Direct offer a Babybond Nuchal Translucency (NT) Scan (also called a nuchal scan)at between 11 and 13 weeks and 6 days gestation. This uses ultrasound to measure fluid at the back of your baby's neck (this area is called the nuchal fold). If a baby has extra fluid at this point, it's a marker for an extra chromosome and they may have Down's syndrome and you'll be counselled to see if you want further diagnostic tests to find out for sure.

·         NIPT scan: This test combines a non-invasive pre-natal blood screening test for Down's syndrome (called Harmony) with a 30-minute diagnostic scan to check viability and dates. It's performed between 10 and 22 weeks.

Second trimester scans

Many of the detailed scans available between 12 and 24 weeks use the latest 4DFREEVIEW™ultrasoundtechnology. These include:

·         Anomaly scans: This 40-minute scan is performed between 19 and 24 weeks and measures your baby's growthand checks internal organs and is probably the most important scan you'll have in pregnancy. Also available on the NHS, anomaly scans include sexing of your baby (but only if requested).

Other important second trimester scans include the Babybond Gender Scan at between 16 and 23 weeks and the JustGender™scan at 18 to 30 weeks.

Final trimester scans

The medical purpose of these baby scans is always to check on your baby's growth, wellbeing and presentation (position). If you’ve previously lost a baby at this stage in pregnancy you may appreciate the reassurance of extra monitoring scans to check on your baby’s wellbeing at this time.

Ultrasound Direct offer:

·         Growth scans: Offered between 24 to 34 weeks, these can measure your baby's growth and estimate fetal weight.

·         4D bonding scans: Available between 24 and 34 weeks, these scans use 4D imaging techniques for 20 minutes, to measure your baby’s growth and estimate fetal weight.

·         Presentation scans: From 37 weeks onwards, these scans can check if your baby and placenta are in the right positions for birth.

For a complete list of all scans offered pre and during pregnancy go to Ultrasound Direct.

What parents say about Ultrasound Direct

Ultrasound Direct actively obtain verified customer reviews via TrustPilot, one of the world’s leading review aggregators. The company cannot influence the reviews collected and welcome feedback from their clients. TrustPilot actively collect daily reviews from Ultrasound Direct clients and have currently in access of 5,000+ on record. Here’s a snapshot of recent feedback from their clients.

‘Was amazing experience!!’

“I loved it!! My scan visit was on Sunday 8 April!! Both ladies were very polite, doctor who took the scan was very nice and gentle.” Adelina Cani

‘Useful information’…

“The lady was lovely and gave us a lot of useful information.” Kelly Maxwell

‘Excellent from booking-in to the scan’

“Excellent from booking in to the scan, great service.” Danny Youles

‘Put my mind at rest about everything’

“Excellent experience and price. Receptionist and sonographer were lovely and welcoming and put my mind at rest about everything. Would definitely recommend/return.” Kelly-marie Robinson

‘Huge peace of mind’

“Appointment for early scan was well worth the money spent. We were seen slightly early than scheduled appointment so no waiting around, enjoyed being able to see scan on big screen whilst it was being performed and felt more time spent so we can watch, sonographer was kind and caring, lots of photos printed. Huge peace of mind having early scan, would recommend.” Kirsty Morgan

‘Explained the whole thing’

“Lovely staff very friendly and took time to get to know us and our situation. Explained the whole thing.” Samantha Fisher

References

[i]https://www.tommys.org/pregnancy-information/im-pregnant/early-pregnancy/how-common-miscarriage

[millioninsightsreports]

Next Generation Sequencing (NGS) Market Development trends, Industry Chain and Technology Analysis to 2025

02th May 2019: The global Next Generation Sequencing Market is anticipated to reach USD 21.4 billion by 2025. NGS market is expected to show a tremendous growth on account of its wide applications in the treatment of cancer. NGS is the process of identifying accurate order of nucleotides within a RNA or a DNA molecule. Advancement of NGS has helped biological and medical discovery and research. It has helped in various applied fields which includes biotechnology, forensic research, virology and medical diagnosis. NGS has made possible sequencing of DNA of various species including the human genome.

Introduction of advanced genetic sequencing and development of advance techniques for whole genomes are the major drivers contributing to the overall market growth. Increasing incidences of cancer and infectious diseases coupled with aging population is expected to fuel the demand for these technologies. Further, the overall cost of genome sequencing is expected to reduce drastically on account of rapid development through research and innovation. High capacity genome sequencing has been contributing significantly towards the market growth.

Get a Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/next-generation-sequencing-ngs-market/request-sample

NGS has wide applications in the field of exome and genome sequencing. They are widely used in the treatment of infectious disease and cancer. NGS has shown a key presence in pathogen analysis which has been helpful in the treatment of infectious diseases. The need for effective diagnosis for cancer and high growing usage of combinational biomarkers are other factors contributing to the growth of the market in recent years.

NGS has been mostly a topic of research and development in the previous decade. At present they find applications in the field of oncology, prenatal testing, HLA testing, idiopathic diseases, and medical research. Research and development in the field of HLA and prenatal testing have provided new avenues to doctors in gaining insights during organ matching and organ rejection.

The development in the treatment of genetic anomalies and diseases with the help of prenatal genome sequencing has been driving the NGS market. This technology has also helped the pharmaceutical companies in developing essential drugs for the treatment of cancer and infectious diseases. Growing concerns and increasing incidences of cancer is expected to be the major driving factor for the development of NGS.

NGS in the field of organ transplant provides great opportunities over the forecast period. It is important that the characteristics of both the donors and the acceptors match for a successful transplant. NGS helps in studying the immune response to the transplanted organ. Medical tourism development in countries including the U.S, Israel, Singapore and Australia provide bright prospects for overall growth of the market.

Next generation sequencing market is segmented as target, genome, exon and resequencing. The largest share is held by target sequencing followed by genome sequencing. Development of whole genome sequencing capabilities is expected to show a significant growth over the forecast period. Whole genome technology is relatively new and is gaining popularity with the development of high throughput. This high throughput has helped in reducing complications associated with whole genome sequencing.

NGS includes sample enrichment, DNA tagging, library preparation, sample quality assurance, DNA quantification, data storage, genetic data assembly, analysis and interpretation. With the increase in volume of whole genome sequencing, next generation data analysis is expected to observe a significant growth over the forecast period.

Government regulatory bodies play a vital role in overall development and usage of these technologies. Medical device manufacturers in the U.S. are under the strict vigilance of Food and Drug Administration (FDA). In 2013, FDA approved four next generation gene sequencing devices which is expected to help physicians in taking a broader look at the patient’s genetic makeup. Two of the approved devices is expected to help in detecting DNA changes in the treatment of cystic fibrosis.

North America is expected to observe highest demand in the global industry on account of the well-developed healthcare sector and implementation of advanced research infrastructure. Similarly, Western Europe is expected to show a substantial demand over the forecast period on account of increasing emphasis by the regional government on healthcare facilities coupled with the stringent regulatory framework. Asia Pacific and the Middle East are expected to observe significant growth on account of the increasing government initiatives to establish proper healthcare infrastructure in developing economies including China, India, Japan and UAE.

Browse Full Research Report @ https://www.millioninsights.com/industry-reports/next-generation-sequencing-ngs-market

The NGS market is dominated by few players with the help of proprietary platforms. The key industry players include Life Sciences (Roche), Thermo Fischer Scientific, Illumina and Pacific Biosciences. Other major players operating in the market include Partek Inc., Genomatix Software GmbH, Macrogen Inc., Life Technologies Corp, Perkin Elmer inc., Oxford Nanopore Technologies Ltd., Knome Inc, Agilent Technologies Inc., Biomatters Ltd., CLC Bio (Qiagen), Pacific Biosciences, BGI (Beijing Genomics Institute), DNASTAR Inc, GATC Biotech and Qiagen N.V.

Market Segmentation

NGS Outlook, by Application (Revenue, USD Million; 2014 - 2025)

   • Reproductive Health

       • NIPT

       • PGT

       • Newborn/Genetic Screening

   • Oncology

   • HLA Typing/Immune System Monitoring

   • Metagenomics, Epidemiology & Drug Development

   • Agrigenomics & Forensics

   • Consumer Genomics

   • Clinical Investigation

       • Idiopathic Diseases

       • Inherited Diseases

       • Infectious Diseases

       • Non-Communicable / Other Diseases

NGS Outlook, by Technology (Revenue, USD Million; 2014 - 2025)

   • Targeted Sequencing Analysis

       • DNA Based Targeted Sequencing Analysis

       • RNA Based Targeted Sequencing Analysis

   • Whole Genome Sequencing

   • Whole Exome Sequencing

NGS Outlook, by Workflow (Revenue, USD Million; 2014 - 2025)

   • Pre-sequencing

       • NGS Library Preparation Kits

       • NGS Semi-automated Library Preparation

       • NGS Automated Library Preparation

       • Clonal Amplification

   • Sequencing

       • Data Analysis

           • Primary Data Analysis

           • Secondary Data Analysis

           • Tertiary Data Analysis

NGS Outlook, by End-use (Revenue, USD Million; 2014 - 2025)

   • Academic Research

   • Clinical Research

   • Hospitals & Clinics

   • Pharma & Biotech Entities

   • Other Users

NGS Outlook, by Region (Revenue, USD Million; 2014 - 2025)

   • North America

       • U.S.

       • Canada

   • Europe

       • Germany

       • UK

   • Asia Pacific

       • China

       • Japan

   • Latin America

       • Brazil

   • Middle East & Africa

       • South Africa    

For More Information visit https://millioninsightsresearch.blogspot.com

[devinsena]

England Pushes To End Early-Sex Tests, Sex-Selective Abortions

On September 18th, politicians in England called for review of the availability of early-sex determination for pregnant women in an attempt to stop sex-selective abortions.  

In the United Kingdom, abortion is legal in the first twenty-four weeks of pregnancy.

A recent discovery in the medical field now enables pregnant women to determine the sex of a baby after the first nine weeks, with a 98% confidence, through a simple draw of the mother's blood. The test is called the Non-Invasive Prenatal Test (NIPT) and most clinics provide it at a cost of £150-£200.

With the development of this new technology, mothers can find out the gender of their babies at nine weeks instead of mid-way through the second trimester, giving them up to two and a half months to have an abortion.

Labour MP Naz Shah said it was “morally wrong” that women were using the Non-Invasive Prenatal Test (NIPT) to determine whether or not they were pregnant with a girl, and then scheduling an abortion based on the results.

The Labour Party is calling for the government to put more regulations on the accessibility to the test. Women have posted quotes in public forums on the BBC, showing that gender will influence whether they get an abortion.

"I need a son to heal me… My only bet is NIPT followed by continuation, only if it's a boy," one woman on the forum said.

Clare McCarthy, a spokesperson for Right To Life UK, told CNA she agrees with the need for government action to address the problem of sex-selective abortion.

"This BBC investigation adds to a growing body of evidence that we have a sex-selective abortion problem here in the UK,” said McCarthy.

“It’s time for the Government to stop denying there is a problem here and take urgent action to put in place a ban on sex-selective abortion.”

Many women are now abusing the power most parents are thrilled to use to prepare for the arrival of a boy or a girl. Yet, women intent on having sex-selective abortions choose to use this new technology to determine whether they will have the baby at all.

A life is a life. Boy or girl.

source http://humandefense.com/england-pushes-to-end-sex-selective-abortions/